WilmerHale has advised Xilio Therapeutics on the offering, and Cooley has advised the underwriter. Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company, announced the pricing...
Xilio Therapeutics Closes $50 Million Public Offering
Xilio Therapeutics’ $2.1 Billion Collaboration With AbbVie
Latham & Watkins advised AbbVie on the transaction, and Ropes & Gray advised Xilio Therapeutics. Xilio Therapeutics (Nasdaq: XLO) announced a strategic collaboration and option agreement...
Gilead Sciences’ $647.5 Million License Agreement with Xilio Therapeutics
Ropes & Gray and Wilmer Cutler Pickering Hale and Dorr represented Xilio Therapeutics, Inc. in the deal. Xilio Therapeutics, Inc.(Nasdaq: XLO), announced it has entered into...



























